Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 7 | Steven P. Treon, MD, PhDOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT01096810 |
| Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma |
| terminated |
| Phase 2 |
| 20 |
| Jagannath, Sundar, M.D.INDIV |
| 1 |
| Jul 22, 2016 |
| clinicaltrials |
| NCT02739594 | Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma(COMPARE) | terminated | Phase 3 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Jul 22, 2016 | clinicaltrials |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 5 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | terminated | Phase 2 | 17 | University of UtahOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Jun 10, 2016 | clinicaltrials |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2016 | clinicaltrials |
| NCT01182233 | Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation | terminated | Phase 1 | 4 | University of RochesterOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT01807286 | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01578343 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma(ZOLINZA) | terminated | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy | terminated | Phase 1 / Phase 2 | 62 | CephalonINDUSTRY | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | terminated | Phase 2 | 43 | Asan Medical CenterOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)(VEIL) | terminated | Phase 2 | 1 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | terminated | Phase 2 | 6 | Januario Castro, M.D.OTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | terminated | Phase 2 | 5 | Januario Castro, M.D.OTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 16, 2015 | clinicaltrials |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 10 | Georgetown UniversityOTHER | 1 | Dec 15, 2015 | clinicaltrials |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | terminated | Phase 2 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 7, 2015 | clinicaltrials |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 5 | Duke UniversityOTHER | 1 | Jul 15, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | terminated | Phase 3 | 48 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 6 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | terminated | Phase 2 | 12 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00748631 | Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.(KYPHOK) | terminated | N/A | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 24, 2015 | clinicaltrials |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | terminated | Phase 3 | 19 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00891033 | Panobinostat/Velcade in Multiple Myeloma | terminated | Phase 1 | 12 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01449539 | Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization | terminated | N/A | 8 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | NYU Langone HealthOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | terminated | Early Phase 1 | 7 | Washington University School of MedicineOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | terminated | Phase 3 | 800 | CTI BioPharmaINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Aug 8, 2016source: clinicaltrials